PolarityTE, Inc.

PTE · NASDAQ Capital Market · USD

0,241USD

−0,002 (−0,82 %)Stand 15. Juni, 20:00

Vortag 0,243

Kennzahlen

Eröffnung
0,2377
Vortag
0,243
Tagesspanne
0,23 – 0,2534
52 Wochen
0,20 – 1,90
Volumen
8,32 Mio.
Ø Volumen
446.876
Börsenwert
1,78 Mio. $
KGV
–
Gewinn je Aktie (TTM)
–
Dividendenrendite
–
Beta
1,2
Nächste Zahlen
–

Finanzen

Gerade nicht verfügbar.

Bewertung

Gerade nicht verfügbar.

Analysten

Einstufungen

Gerade nicht verfügbar.

Kursziel

Gerade nicht verfügbar.

Quartalszahlen

Gerade nicht verfügbar.

Dividenden und Splits

Gerade nicht verfügbar.

Aktiensplits

Gerade nicht verfügbar.

Eigentümer

Institutionen

Gerade nicht verfügbar.

Insider-Geschäfte

Gerade nicht verfügbar.

Vergleichbare Unternehmen

Gerade nicht verfügbar.

Über das Unternehmen

Based in Salt Lake City, Utah, PolarityTE, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of regenerative tissue products and biomaterials. Its offerings serve the medical, biomedical engineering, and material sciences sectors across the United States. The company operates through two primary divisions: Regenerative Medicine Products and Contract Services. PolarityTE's key product is SkinTE, a specialized tissue solution employed for the repair, reconstruction, replacement, or augmentation of skin in patients. Its applications encompass treating acute or chronic wounds, burns, surgical reconstruction, scar revision, and the removal of dysfunctional skin grafts. In addition to its product line, the firm also provides contract research services. The company's pipeline includes SkinTE Cryo, which facilitates multiple deployments from a single harvest through a cryopreservation process, and a SkinTE point-of-care device designed for immediate processing and application of SkinTE directly after initial harvest. PolarityTE is also advancing PTE 11000, an allogenic, biologically active dressing engineered to accelerate healing in both wound care and aesthetic contexts, alongside other promising tissue regeneration products.

CEO
Richard Hague
Mitarbeitende
42
Hauptsitz
Salt Lake City, UT, US
Sektor
Healthcare
Branche
Biotechnology
Börsengang
16. Aug. 1999

Nachrichten

Gerade nicht verfügbar.

Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.